CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC student breaks world record in competitive speedcubing
December 19, 2025
UC computer science student Sujan Feist set a new world record in speedcubing at competition this month in Coshocton, Ohio. Feist is the reigning world champion in the 2x2 division.
A partnership to end pancreatic cancer
December 19, 2025
Since 2010, BSI Engineering has raised more than $1.2 million for pancreatic cancer research at the University of Cincinnati Cancer Center in honor of a friend and inspiration to BSI’s founders, Bryan Speicher.
Bazinga! UC physicist cracks ‘Big Bang Theory’ problem
December 19, 2025
A physicist at the University of Cincinnati and his colleagues figured out something two of America’s most famous fictional physicists couldn’t: theoretically how to produce subatomic particles called axions in fusion reactors.